Document:

ex10_2.htm

EXHIBIT 10.2

 

ANTRIABIO, INC.

 

REPAYMENT AGREEMENT

 

This REPAYMENT AGREEMENT (“Agreement”) is made and entered into as of this 26th day of March, 2014 (the “Effective Date”), by and between AntriaBio, Inc. (“Antria”) and Konus Advisory Group, Inc. (“Konus”).  Antria and Konus are sometimes referred to herein collectively as the “Parties.”  

RECITALS

WHEREAS, on June 18, 2012, Antria entered into an employment agreement (the “Employment Agreement”) with Mr. Nevan Elam to serve as Chief Executive Officer of Antria;

WHEREAS, pursuant to the terms of the Employment Agreement, Mr. Elam agreed to serve as Antria’s Chief Executive Officer as a consultant, subject to Mr. Elam committing full time to the business of Antria;

WHEREAS, pursuant to the terms of the Employment Agreement, Antria agreed to compensate Mr. Elam in an amount equal to $230,000 per year;

WHEREAS, pursuant to a mutual understanding between Mr. Elam and Konus, the amounts owed to Mr. Elam pursuant to the terms of the Employment Agreement were to be paid directly to Konus;

WHEREAS, Mr. Elam and Antria have entered into an amended and restated employment agreement (the “Amended and Restated Employment Agreement”) whereby Mr. Elam has committed to become Antria’s Chief Executive Officer on a full-time basis;

WHEREAS, upon the effective date of the Amended and Restated Employment Agreement, any amounts owed to Mr. Elam pursuant to the terms of the Amended and Restated Employment Agreement will be paid directly to Mr. Elam in accordance with Antria’s payroll practices for executives;  

WHEREAS, on July 1, 2012, Antria entered into a consulting agreement (the “Consulting Agreement”) with Dr. Hoyung Huh, whereby Dr. Huh agreed to provide Antria consulting services including, but not limited to, serving on Antria’s board of directors as lead independent director,  assisting Antria in efforts to obtain funding and assisting in business development activities;

WHEREAS, pursuant to a mutual understanding between Dr. Huh and Konus, the amounts owed to Dr. Huh pursuant to the Consulting Agreement were to be paid directly to Konus;

WHEREAS, Dr. Huh and Antria have agreed to enter into a termination agreement (the “Termination Agreement”) whereby Dr. Huh and Antria have mutually agreed to terminate the

  

  

  

Consulting Agreement in accordance with the Termination Agreement and that from the effective date of the Termination Agreement, Antria will no longer have any obligation to compensate Dr. Huh as a consultant in accordance with the Consulting Agreement;

 

WHEREAS, On July 2, 2012, the Parties entered into an advisory agreement (the “Advisory Agreement”) whereby Konus agreed to provide Antria services including, but not limited to, finance and strategy, clinical design, project management and portfolio assessment;  

WHEREAS, pursuant to the terms of the Advisory Agreement, Antria agreed to pay Konus a monthly retainer in the amount of $9,000 per month to cover general and administrative matters plus an hour fee ranging from $100 to $700 per hour for additional services provided to Antria;

 

WHEREAS, all amounts due and owing to Konus collectively under the Employment Agreement, Consulting Agreement and Advisory Agreement (collectively, the “Konus Agreements”) have been accrued; 

WHEREAS, as of the Effective Date, the total amounts due and owing to Konus collectively under the Konus Agreements is $1,182,644 (the “Balance”); and 

WHEREAS, the Parties, having discussed this matter, desire to facilitate the repayment of the Balance by Antria through: (i) the issuance of $275,000 of Antria’s shares of common stock (the “Payment Shares”) to Konus with such Payment Shares to be valued at $0.26 per share; and (ii) a cash payment of $907,644 (the “Cash Payment”) to be paid at such time as mutually agreed to by the Parties.

 NOW, THEREFORE, for and in consideration of the mutual promises contained in this Agreement, and for other good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: 

AGREEMENT

1.           Payment by Antria.  Antria agrees to pay Konus the total amount of $1,182,644, which represents the entire Balance, in two (2) payments.  The first payment will be made through the issuance of $275,000 Payment Shares to Konus no later than three (3) business days following the Effective Date and the second payment will be made in the form of the Cash Payment equal to $907,644 or a series of Cash Payments equal to $907,644, with such Cash Payments to be paid on such date as mutually agreed to by the Parties.     

2.           Representations and Warranties of Konus.  Konus hereby makes the following representations and warranties to Antria  with the intention that Antria rely on such representation and warranties in issuing the Payment Shares to Konus and in complying with its obligations under applicable federal and state securities laws:

	
  (a)   

	
Konus is acquiring the Payment Shares for Konus’s own account and for investment purposes only and not with a view towards, or for resale in connection with, the public sale or distribution thereof; provided however, by making the representations herein, Konus does not agree to hold any of the Payment Shares

  

-2-

  

for any minimum or other specific term.  Konus also represents that the entire legal and beneficial interest of the Payment Shares is being acquired for, and will be held for, Konus’s account only.

	
  (b)   

	
Konus recognizes that investment in the Payment Shares involves substantial risks and has taken full cognizance of and understands all of the risks related to the acquisition of the Payment Shares.  In making its decision to invest in the Payment Shares, Konus has relied on the information provided by Antria and certain documents and materials delivered by Antria, and on Konus’s own independent investigations and/or those of Konus’s own professional tax and other advisors.  Konus has been given the opportunity to obtain information and to examine all documents relating to Antria, and to ask questions of, and to receive answers from, the officers of Antria concerning Antria, the officers and directors and the terms and conditions of this investment and to obtain any additional information, to the extent Antria possesses such information or could acquire it without unreasonable effort or expense, to verify the accuracy of any information previously furnished.  All such questions have been answered to the full satisfaction of Konus, and all information and documents, records and books pertaining to this investment, which Konus has requested have been made available to Konus.

	
  (c)   

	
Konus believes that it has such knowledge and experience in financial and business matters to evaluate the merits and risks of the prospective investment in the Payment Shares and is able to (i) hold the Payment Shares for an indefinite period of time, (ii) bear the economic risk of its investment in the Payment Shares, and (iii) withstand a complete loss of such investment.

	
  (d)   

	
Konus is aware that the Payment Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state, and Antria intends to rely upon the exemption available under Section 4(a)(2) of the Securities Act in connection the issuance of the Payment Shares based in part upon representations set forth herein.  Konus understands that the Payment Shares may not be offered, sold, transferred, pledged or hypothecated to any person in the absence of registration under the Securities Act or an opinion of counsel satisfactory to Antria that an exemption from such registration is available for sales of the Payment Shares by Konus.  Konus understands that Antria does not plan, and is under no obligation to provide for, registration of the Payment Shares in the future.  Accordingly, any subsequent sale by Konus of part or all of the Payment Shares will be possible only if an exemption from the applicable registration provisions of federal and state law is available at the time of the proposed disposition.  

	
  (e)   

	
Konus represents and warrants that it is aware of no facts or circumstances indicating that the undersigned is or may be deemed to be an “underwriter” (as defined in the Securities Act) of securities of Antria.

  

-3-

  

	
(f)  

	
Konus understands that Antria may have been “shell company” as contemplated under Rule 144(i) and Rule 144 may not be available to the Konus if, or until, Antria is eligible to rely on Rule 144(i)(2).

	
  (g)   

	
Konus has the power and authority to execute and comply with the terms of this Agreement. 

	
  (h)   

	
Konus understands that the Payment Shares are “restricted securities” (as that term is defined in paragraph (a)(3) of Rule 144 under the Securities Act).

	
  (i)   

	
Konus is an “accredited investor” within the meaning of Rule 501(a)(1), (2), (3) or (7) of the Securities Act and is able to bear the economic risk of losing its entire investment in Antria.  

	
  (j)   

	
Konus understands that nothing in this Agreement constitutes legal, tax or business advice.

	
  (k)   

	
Konus understands that any certificate representing the Payment Shares shall bear the following restrictive legend:

 

“THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”).  THESE SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) IF THE SECURITIES HAVE BEEN REGISTERED IN COMPLIANCE WITH THE REGISTRATION REQUIREMENTS UNDER THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS (C) IN COMPLIANCE WITH THE EXEMPTION FROM THE REGISTRATION REQUIREMENTS UNDER THE SECURITIES ACT IN ACCORDANCE WITH RULE 144 THEREUNDER, IF APPLICABLE, AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, OR (D) IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT OR ANY APPLICABLE STATE LAWS AND REGULATIONS GOVERNING THE OFFER AND SALE OF SECURITIES, AND THE HOLDER HAS, PRIOR TO SUCH SALE, FURNISHED TO THE COMPANY AN OPINION OF COUNSEL OF RECOGNIZED STANDING, OR OTHER EVIDENCE OF EXEMPTION, REASONABLY SATISFACTORY TO THE COMPANY.  HEDGING TRANSACTIONS INVOLVING THE SECURITIES REPRESENTED HEREBY MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH U.S. SECURITIES LAWS.” 

 

3.           Representations and Warranties of Antria.  Antria represents and warrants to Konus that, as of the date of this Agreement:

 

(a)               The Payment Shares when issued will be duly authorized, validly issued, fully paid and nonassessable.

  

-4-

  

(b)               Antria has the full power and lawful authority to consummate its obligations and transactions contemplated by this Agreement on the terms and conditions set forth in this Agreement, and no permit, consent, approval, authorization or other order of or filing with any other person or entity is required in connection with such authorization, execution, delivery, and consummation, and the execution, delivery and performance by Antria of this Agreement and the transactions contemplated by this Agreement constitute the valid and binding obligations of Antria, enforceable against Antria in accordance with the terms of this Agreement, and will not result in the violation or breach of any term or provision of, or constitute (with or without due notice or lapse of time or both) a default under any agreement or instrument to which Antria is a party or by which Antria is bound.

 

4.           Severability.  Should any of the provisions of this Agreement be rendered invalid by a court or governmental agency of competent jurisdiction, it is agreed that this shall not in any way or manner affect the enforceability of the other provisions of this Agreement, which shall remain in full force and effect.

 

5.           Governing Law, Venue.  This Agreement shall be governed by the laws of the State of Delaware, not including its choice-of-law rules.  It is the express intent of the Parties that this Agreement be binding and enforceable under the principles of law applicable to contract and that, subject to an appropriate order protecting its confidentiality, the Agreement itself may be used as evidence in a subsequent proceeding in which any party alleges a breach of this Agreement, so long as this Agreement is filed under seal or other measures are taken to ensure the confidentiality of its terms.

6.           Entire Agreement.  This Agreement constitutes the entire agreement and final understanding between the Parties as to the payment of the Balance.  Any modification of, or addition to, this Agreement must be in writing signed by the Parties.

 

7.           Acknowledgement.  Pettijohn hereby affirms and acknowledges that he has read and understands the foregoing Agreement.  Pettijohn represents that he enters into this Agreement freely and voluntarily.

[THE REMAINDER OF THIS PAGE WAS INTENTIONALLY LEFT BLANK]

  

-5-

  

 

 

IN WITNESS WHEREOF, the undersigned have executed this Agreement on the date shown below.

	
  

	
ANTRIABIO, INC.

By: /s/ Steve Howe                                              

Title:  Director

Date: March 26, 2014

 

 

	
  

	
KONUS ADVISORY GROUP, INC.

By: /s/ Nevan Elam                                              

 

Title:  Managing Member

Date: March 26, 2014

 

 

 

 

Signature Page to Repayment Agreementex10_3.htm

EXHIBIT 10.3

 

THIS AGREEMENT is made and entered into effective as of March 26, 2014 by and between AntriaBio, Inc. a Delaware corporation, having an address of 890 Santa Cruz Avenue, Menlo Park , California 94025 (“AntriaBio” or the “Company”), and Sankaram Mantripragada (the “Executive”).  This Agreement amends and replaces the Employment Agreement entered into on April 1, 2012 between the Company and the Executive (the “Original Agreement”) in its entirety.

 

In consideration of the mutual promises, terms, provisions and conditions set forth in this Agreement, the parties hereby agree as follows:

 

1.           Employment.  Subject to the terms and conditions set forth in this Agreement, the Company hereby offers and the Executive hereby accepts employment.

 

2.           Term.  The Executive’s employment hereunder shall commence effective as of March 26, 2014 (the “Effective Date”) and shall continue until terminated on the terms and conditions set forth herein.  The Term of this Agreement is hereafter referred to as “the term of this Agreement” or “the term hereof.”

 

3.           Capacity and Performance; Location.

 

(a)           During the term hereof, the Executive shall serve as the Chief Scientific Officer of the Company, reporting directly to the Chief Executive Officer or such other Officer as determined by the Chief Executive.

 

(c)           During the term hereof, the Executive shall devote sufficient time and his best efforts, business judgment, skill and knowledge to the advancement of the business and interests of the Company and to the discharge of his duties and responsibilities hereunder.  The Executive shall comply with all written policies of the Company in effect from time to time and shall observe and implement those resolutions and directives of the Chief Executive Officer or the Board of Directors, as made or issued from time to time.  The Executive agrees that under no circumstances shall he undertake any other form of employment or consulting that would conflict with the interests of the Company.

 

(d)           The Executive will be expected to work out of the Company’s lab facilities currently located in Colorado.

 

4.           Compensation and Benefits.  As compensation for all services performed by the Executive hereunder during the term hereof, and subject to performance of the Executive’s duties and obligations pursuant to this Agreement:

 

(a)           Base Salary.  From the Effective Date , the Company shall pay the Executive a base salary of Two Hundred Ninety-five Thousand Dollars ($295,000)  per annum (the “Base Salary”), payable in accordance with the payroll practices of the Company for its executives, but no less than once per each month.  

 

  

  

  

               (b)           One Time Bonus.  The Company will pay the Executive a one-time bonus of $100,000, when animal testing related to AB101, also known as InsuLAR, and also known as a weekly basal insulin product, begins either in the USA or outside the USA.  The Company will pay the Executive a one-time bonus of $175,000 upon initiation of a human clinical trial either in the USA or outside the USA related to AB101.  The one-time bonus paid upon the occurrence of either or both of these two events shall not be considered or offset to any degree by the Company in determining the annual salary, annual bonus, expense reimbursement, benefits, or severance.

 

(c)           Bonus Compensation.  During the term hereof, the Executive shall have the opportunity to earn an annual performance bonus equal to up to 40% of the Executive’s Base Salary (“Target Bonus”) based upon performance criteria set by the Board in its sole discretion on an annual basis, it being understood and agreed that notwithstanding the Target Bonus, there shall be no minimum or maximum with respect to any potential annual bonus.  The Board shall conduct a performance review of the Executive at least once a year on or prior to February 1 of each year, commencing in 2015.  The Company may, from time to time, pay such other bonus or bonuses to the Executive as the Board or a compensation committee of the Board, in its sole discretion, deems appropriate.  In order to receive the annual performance bonus, the Executive must continue to be employed by the Company through the end of the period with respect to which the annual performance bonus has been earned.  The annual performance bonus will be paid to the Executive at such time as bonuses for the applicable period are regularly paid to senior executives of the Company; provided, however, in no event will the annual performance bonus be paid later than February 28 of the following calendar year.  

(d)           Equity Incentives.  The Executive shall be eligible to participate in the Company’s equity incentive plans, if any, and any options or restricted stock granted under such plan shall be deemed to be Stock Options for purpose of this Agreement.  In addition, Executive shall be eligible to participate in the Company’s Restricted Stock Unit Plan, if any.  Nothing contained herein shall be construed to limit the Company’s ability to amend, suspend, or terminate any equity incentive plan at any time without providing Executive notice, and the right to do so is expressly reserved.

 

(e)           Vacations.  During the term hereof, the Executive shall be entitled to four (4) weeks of vacation per annum, to be taken and approved by the Chief Executive Officer, at such times and intervals as shall be determined by the Executive and subject to the reasonable business needs of the Company.  Vacation time shall not cumulate from year to year.  

 

(f)           Employee Benefits.  During the term hereof, Executive shall be entitled to participate in health, dental, vision, life insurance, retirement and other benefits (“Benefits”) provided generally to similarly situated employees of the Company.  Such participation shall be subject  to (i) the terms of the applicable plan documents, (ii) generally applicable Company policies and (iii) the discretion of the Board or any administrative or other committee provided for in or contemplated by such plan.  Nothing contained herein shall be construed to limit the Company’s ability to amend, suspend, or terminate any employee benefit plan or policy at any time without providing Executive notice, and the right to do so is expressly reserved. Company shall pay all premiums for a Directors and Officers liability insurance policy that covers the Executive.

  

  

  

 

(g)           Business Expenses.  The Company shall pay or reimburse the Executive for all reasonable and necessary business expenses incurred or paid by the Executive in the performance of his duties and responsibilities hereunder, subject to any maximum annual limit and other restrictions on such expenses set by the Board for senior executives of the Company, and to such reasonable substantiation and documentation as may be specified by the Company from time to time.  

 

5.           Termination of Employment.  Executive’s employment hereunder may terminate as set forth below.

 

(a)           Death.   In the event of the Executive’s death during the term hereof, the Executive’s employment hereunder shall immediately terminate.  In that event, the Company shall pay to the Executive’s designated beneficiary or, if no beneficiary has been designated by the Executive, to his estate, any earned and unpaid Base Salary through the date of termination plus an amount equal to his annual Target Bonus.   The Company shall have no further obligation or liability to the Executive or his estate.  

 

(b)           Disability.  In the event that the Executive becomes disabled during his employment hereunder through any illness, injury, accident or condition of either a physical or psychological nature and, as a result, is unable to perform the essential functions of his position hereunder, with or without reasonable accommodation, for at least eighty (80) days during any period of one-hundred eighty (180) consecutive calendar days, the Company may terminate the Executive’s employment with thirty (30) day written notice.  In that event, the Company shall pay to the Executive, any earned and unpaid Base Salary and his pro-rated annual Target Bonus through the date of termination. The Company shall have no further obligation or liability to the Executive.

 

(c)           By the Company for Cause.  Employment with the Company is not for a specific term and can be terminated by the Executive or by the Company or its successors at any time for any reason, with or without Cause, subject to the following terms.  As used herein, “Cause” shall mean (i) any act that materially violates this agreement or the employment policies of the Company, (ii) any willful misconduct by Executive that may result in harm to he Company or its employees, consultants or directors, (iii) misappropriation (or attempted misappropriation) by Executive of any assets or business opportunities of the Company, (iv) embezzlement or fraud committed (or attempted) by Executive, or at his direction, (v) Executive’s conviction of, indictment for, or pleading “guilty” or “no contest” to, (x) a felony or (y) any other criminal charge that has a material adverse impact on the performance of Executive’s duties to the Company or otherwise result in material injury to the reputation or business of the Company.  Upon the giving of notice of termination of the Executive’s employment hereunder for Cause, the Company shall not have any further obligation or liability to the Executive, other than for Base Salary earned and unpaid through the date of termination.  Any unvested stock options shall be forfeited and vested stock options not exercised prior to termination shall expire and no longer be exercisable.

  

  

  

 

(d)           By the Company without Cause.  The Company may terminate the Executive’s employment hereunder without Cause at any time upon fourteen (14) days advance written notice.

 

(e)           By the Executive.  The Executive may terminate his employment, without cause or with Good Reason, at any time upon at least thirty (30) days’ advance written notice to the Company.  The term “Good Reason” shall mean a material reduction in Executive’s duties or material reduction in compensation, except for a reduction in compensation that affects all members of management on the same percentage basis.

 

(f)           Change in Control.  If the Company terminates the Executive within twelve (12) months following a Change of Control or if Executive terminates for Good Reason within twelve (12) months following a Change of Control, in addition to the Severance Benefits specified in Section 4(g)(i)(A) and (C) below, all Stock Options that are subject to vesting shall have the vesting accelerate and become fully vested, any shares of capital stock of the Company that are subject to a right of repurchase shall have such right of repurchase lapse and units then held by the Executive pursuant to a restricted stock unit plan shall immediately vest and become exercisable.   “Change in Control” means an event or occurrence set forth in any one or more of subsections below (including an event or occurrence that constitutes a Change in Control under one of such subsections but is specifically exempted from another such subsection): 

 

(i)           the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) (an “Acquiring Person”) of beneficial ownership of any capital stock of the Company if, after such acquisition, such Acquiring Person beneficially owns (within the meaning of Rule 13d-3 promulgated under the Exchange Act) 50% or more of either (i) the then-outstanding shares of common stock of the Company (the “Outstanding Company Common Stock”) or (ii) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”); provided, however, that for purposes of this subsection (i), the following acquisitions shall not constitute a Change in Control:  (A) any acquisition directly from the Company, (B) any acquisition by the Company or (C) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company; or

  

(ii)           the consummation of a merger, consolidation, reorganization, recapitalization or statutory share exchange involving the Company or a sale or other disposition of all or substantially all of the assets of the Company (a “Business Combination”), unless, immediately following such Business Combination, all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business

  

  

  

Combination in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively.

(g)           Severance Benefits.

 

(i)           In the event that the Company terminates the Executive’s employment without Cause (as defined above subject to the terms and conditions of this Section 5(g)) or Executive terminates his employment for Good Reason, (A) the Company will pay an amount equal to the Base Salary plus the annual Target Bonus as severance on a monthly basis to the Executive and will provide the continuation of the benefits set forth in Section 4(e) for a period of twelve months (the “Severance Period”) following Executive’s termination, (B) any Stock Options that are subject to vesting shall have vesting accelerated with respect to the number of shares that would have vested during the Severance Period if Executive had remained employed by the Company during such period (and any shares of capital stock of the Company that are subject to a right of repurchase shall have such right of repurchase lapse with respect to the number of shares that would have lapsed during the Severance Period if Executive had remained employed by the Company during such period), and (C) accrued and unused vacation at the time of termination up to a maximum of four weeks shall be paid to Executive.

  

(ii)           The severance amount and benefits continuation set forth in Section 5(g)(i) are referred to herein as the “Severance Benefits.  The continuation of any group health plan benefits shall be to the extent authorized by and consistent with 29 U.S.C. § 1161 et seq. (commonly known as “COBRA”), with the cost of the regular employer portion of the premium for such benefits paid by the Company.  The Executive’s right to receive Severance Benefits under Subsection 5(g)(i) is conditioned upon (x) the Executive’s prior execution and delivery to the Company of a reasonably satisfactory general release of any and all claims and causes of action of the Executive against the Company and its officers and directors, excepting only the right to any compensation, benefits and/or reimbursable expenses due and unpaid under Sections 4 and/or 5(g)(i) of this Agreement, and (y) the Executive’s continued performance of those obligations hereunder that continue by their express terms after the termination of his employment, including without limitation those set forth in Sections 8, 9 and 10.  Any Severance Benefits to be paid hereunder shall be payable in accordance with the payroll practices of the Company for its executives generally as in effect from time to time, and subject to all required withholding of taxes.

 

6.           Effect of Termination.  Upon termination of this Agreement, all obligations and provisions of this Agreement shall terminate except with respect to any accrued and unpaid monetary obligations and vesting acceleration provisions and except for the provisions of Section 7 through (and inclusive of) 20 hereof.

 

7.           Confidential Information; Assignment of Inventions.

 

  

  

  

(a)           The Executive acknowledges that the Company and its Affiliates will continually develop Confidential Information and Proprietary Information (as defined below), that the Executive may develop Confidential Information and Proprietary Information for the Company or its Affiliates, and that the Executive may learn of Confidential Information and Proprietary Information during the course of his employment with the Company.  The Executive agrees that, except as required for the proper performance of his duties for the Company, he will not, directly or indirectly, use or disclose any Confidential Information or Proprietary Information.  The Executive understands and agrees that this restriction will continue to apply after his employment terminates, regardless of the reason for termination.

  

(b)           The Executive agrees that all Confidential Information and Proprietary Information, including, without limitation all work products, inventions methods, processes, designs, software, apparatuses, compositions of matter, procedures, improvements, property, data documentation, information or materials that the Executive, jointly or separately prepared, conceived, discovered, reduced to practice, developed or created during, in connection with, for the purpose of, related to, or as a result of his employment with the Company, and/or to which he has access as a result of his employment with the Company (collectively, the “Inventions”) is and shall remain the sole and exclusive property of the Company.

 

(c)           The Executive by his signature on this Agreement unconditionally and irrevocably transfers and assigns to the Company all rights, title and interest in the Inventions (as defined above, including all patent, copyright, trade secret and any other intellectual property rights therein) and will take any steps and execute any further documentation from time to time reasonably necessary to effect such assignment free of charge to the Company.  The Executive will further execute, upon request, whether during, or after the termination of, his employment with the Company, any and all applications for patents, assignments and other papers, which the Company may deem necessary or appropriate for securing such Inventions for the Company.

 

(d)           Except as required for the proper performance of his duties, the Executive will not copy any and all papers, documents, drawings, systems, data bases, memoranda, notes, plans, records, reports files, data (including original data), disks, electronic media etc. containing Confidential Information or Proprietary Information (“Documents”) or remove any Documents, or copies, from Company premises.  The Executive will return to the Company immediately after his employment terminates, and at such other times as may be specified by the Company, all Documents and copies and all other property of the Company and its Affiliates then in his possession or control.

 

8.           Enforcement of Covenants.  The Executive acknowledges that he has carefully read and considered all the terms and conditions of this Agreement, including the restraints imposed upon him pursuant to Section7hereof.  The Executive acknowledges that the covenants contained in Section 7are reasonably necessary to protect the goodwill of the Company that is its exclusive property.  The Executive further acknowledges and agrees that, were he to breach any of the covenants contained in Section 7hereof, the damage would be irreparable.  The Executive therefore agrees that the Company, in addition to any other remedies available to it, shall be

  

  

  

entitled to preliminary and permanent injunctive relief against any breach or threatened breach by the Executive or any of said covenants, without having to post bond.

 

9.           Conflicting Agreements.  The Executive hereby represents and warrants that the execution of this Agreement and the performance of his obligations hereunder will not breach or be in conflict with any other agreement to which the Executive is a party or is bound and that the Executive is not subject to any covenants against competition or similar covenants that would affect the performance of his obligations hereunder.  The Executive will not disclose to or use any confidential or proprietary information of a third party without such party’s consent.

 

10.           Definitions.  Words or phrases which are initially capitalized or are within quotation marks shall have the meanings provided in this Section 10 and as provided elsewhere herein.  For purposes of this Agreement, the following definitions apply:

 

                (a)           “Affiliates” means all persons and entities directly or indirectly controlling, controlled by or under common control with the Company, where control may be by either management authority or equity interest.

 

(b)           “Confidential Information” means any and all information, inventions, discoveries, ideas, writings, communications, research, engineering methods, developments in chemistry, manufacturing information, practices, processes, systems, technical and scientific information, formulae, designs, concepts, products, trade secrets, projects, improvements and developments that relate to the business of the Company or any Affiliate and are not generally known by others, including but not limited to (i) products and services, technical data, methods and processes, (ii) marketing activities and strategic plans, (iii) financial information, costs and sources of supply, (iv) the identity and special needs of customers and prospective customers and vendors and prospective vendors, and (v) the people and organizations with whom the Company or any Affiliate has or plans to have business relationships and those relationships.  Confidential Information also includes such information that the Company or any Affiliate may receive or has received belonging to customers or others who do business with the Company or any Affiliate and any publication or literary creation of the Executive, developed in whole or in part while the Executive is employed by the Company, in whatever form published the content of which, in whole or in part, relates to the business of the Company or any Affiliate.  Confidential Information shall not include any information or materials that Executive can prove by written evidence (i) is or becomes publicly known through lawful means and without breach of this Agreement by Executive; (H) was rightfully in Executive’s possession or part of Executive’s general knowledge prior to the Effective Date; or (iii) is disclosed to Executive without confidential or proprietary restrictions by a third party who rightfully possesses the information or materials without confidential or proprietary restrictions.

 

(c)           “Person” means an individual, a corporation, an association, a partnership, an estate, a trust and any other entity or organization.

 

(d)           “Proprietary Information” means any and all intellectual property subject to protection under applicable copyright, trademark, trade secret or patent laws if such property is

  

  

  

similar in any material respect with the products and services offered by the Company or any Affiliate.

 

11.           Withholding.  All payments made under this Agreement shall be reduced by any tax or other amounts required to be withheld under applicable law.

 

12.           Assignment.  Neither the Company nor the Executive may make any assignment of this Agreement or any interest herein, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and shall assign its obligations under this Agreement without the consent of the Executive in the event that the Company shall hereafter effect a reorganization, or consolidate with or merge into any other Person, or transfer all or substantially all of its properties or assets to any other Person.  This Agreement shall inure to the benefit of and be binding upon the Company and the Executive, and their respective successors, executors, administrators, heirs and permitted assigns.

 

            13.           Severability.  If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.

 

14.           Waiver.  No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party.  The failure of either party to require the performance of any term or obligation of this Agreement, or the waiver by either party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

 

15.           Notices.  Any and all notices, requests, demands and other communications provided for by this Agreement shall be in writing and shall be effective when delivered in person or by overnight courier or delivery service, or 3 business days after being deposited in the Danish or United States mail, postage prepaid, registered or certified, and addressed to the Executive at his last known address on the books of the Company or, in the case of the Company, at the Company’s principal place of business, to the attention of the Chairman of the Board, or to such other address as either party may specify by notice to the other actually received.

 

16.           Entire Agreement.  This Agreement constitutes the entire agreement between the parties and supersedes all prior communications, agreements and understandings, written or oral, with respect to the terms and conditions of the Executive’s employment.

 

17.           Amendment.  This Agreement may be amended or modified only by a written instrument signed by the Executive and an expressly authorized representative of the Company.

 

18.           Headings.  The headings and captions in this Agreement are for convenience only and in no way define or describe the scope or content of any provision of this Agreement.

 

  

  

  

 

19.           Counterparts.  This Agreement may be executed in two or more counterparts, each of which shall be an original and all of which together shall constitute one end the same instrument.

 

20.           Governing Law.  This Agreement shall be construed and enforced under and be governed in all respects by the laws of the State of Colorado , without regard to the conflict of laws principles thereof

 

21.           Tax Matters.

 

(a)           In the event of an event constituting a change in the ownership or effective control of Company or ownership of a substantial portion of the assets of Company described in Code Section 280G(b)(2)(A)(i) (a “2800 Transaction”), Company shall cause its independent auditors or another person or entity approved by the Company and Executive promptly to review all payments, accelerations, distributions and benefits that have been made to or provided to, and are to be made, or may be made, to or provided to, Executive under this Agreement, the 2012 Plan and any other arrangements providing for payments or benefits contingent on the occurrence of a 280G Transaction (irrespective of whether such payments or benefits are then payable to Executive at that time), and any other agreement or plan under which Executive may individually or collectively benefit (collectively the “Original Payments”), to determine the applicability of Code Section 4999 to Executive in connection with such event.  Company’s independent auditors or such other approved party will perform this analysis in conformity with the foregoing provisions and will provide Executive with a copy of their analysis and determination.  Notwithstanding anything contained in this Agreement to the contrary, to the extent that the Original Payments would be subject to the excise tax imposed under Code Section 4999 (the “Excise Tax”), the Original Payments shall be reduced (but not below zero) to the extent necessary so that no Original Payment shall be subject to the Excise Tax, but only if, by reason of such reduction, the net after-tax benefit received by Executive shall exceed the net after-tax benefit received by him if no such reduction was made.  For purposes of this Agreement, “net after-tax benefit” shall mean (a) the Original Payments which Executive receives or is then entitled to receive from Company that would constitute “parachute payments” within the meaning of Code Section 280G, less (b) the amount of all federal, state and local income taxes payable with respect to the foregoing calculated at the maximum marginal income tax rate for each year in which the foregoing shall be paid to Executive (based on the rate in effect for such year as set forth in the Code as in effect at the time of the first payment of the foregoing), less (c) the amount of the Excise Tax imposed with respect to the payments and benefits described in (a) above.  If a reduction is to occur pursuant to this Section 24(a), the payments and benefits shall be reduced in the following order:  any cash severance to which Executive becomes entitled (starting with the last payment due), then other cash amounts that are parachute payments (starting with the last payment due), then any stock option awards that have exercise prices higher than the then-fair market value price of the stock (based on the latest vesting tranches), then restricted stock and restricted stock units based on the latest awards scheduled to be distributed, and then other stock options based on the latest vesting tranches.  The fees and expenses of Company’s auditor or any other party for services in

 

 

  

  

  

 

 connection with the determinations and calculations contemplated by this provision will be borne by Company.

 

(b)           The intent of the parties is that payments and benefits under this Agreement comply with or be exempt from Section 409A of the Internal Revenue Code of 1986, LID amended (“Code Section 409A”) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith.  If the Executive notifies the Company (with specificity as to the reason therefor) that he believes that any provision of this Agreement (or of any award of any compensation or benefits) would cause him to incur any additional tax or interest under Code Section 409A and the Company concurs with such belief or the Company independently makes such determination, the Company shall, after consultation with the Executive, to the extent legally permitted and to the extent it is possible to timely reform the provision to avoid taxation under Code Section 409A, reform such provision to attempt to comply with Code Section 409A through good faith modifications to the minimum extent reasonably appropriate to conform with Code Section 409A.  To the extent that any provision hereof is modified in order to comply with or be exempt from Code Section 409A, such modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit to both the Executive and the Company of the applicable provision without violating the provisions of Code Section 409A.

 

(c)           For purposes of the application of Treasury Regulation § 1.409A-1(b)(4) (or any successor provision), each payment in a series of payments will be deemed a separate payment.

 

(d)           If the termination of employment giving rise to the severance benefits described in Sections 5 or 6 is not a “separation from service” within the meaning of Treasury Regulation § 1.409A-1(h)(1), then to the extent necessary to avoid the imposition of any accelerated or additional tax under Code Section 409A, such benefits will be deferred without interest until Executive’ experiences a separation from service.

 

If at the time of Executive’s separation from service, (i) he is a specified employee (within the meaning of Code Section 409A and using the identification methodology selected by the Company from time to time), and (ii) the Company makes a good faith determination that an amount payable to Executive constitutes deferred compensation (within the meaning of Code Section 409A) the payment of which is required to be delayed pursuant to the six-month delay rule set forth in Code Section 409A in order to avoid taxes or penalties under Code Section 409A (the “Delay Period”), then the Company will not pay such amount on the otherwise scheduled payment date but will instead pay it in a lump sum on the first business day after such six-month period.  To the extent that any benefits to be provided during the Delay Period is considered deferred compensation under Code Section 409A provided on account of a “separation from service,” and such benefits are not otherwise exempt from Code Section 409A, Executive shall pay the cost of such benefits during the Delay Period, and the Company shall reimburse Executive, to the extent that such costs would otherwise have been paid by the Company or to the extent that such benefits would otherwise have been provided by the Company at no cost to Executive, the Company’s share of the cost of such benefits upon expiration of the Delay Period, and any remaining benefits shall be reimbursed or provided by the Company in accordance with the procedures specified herein.

 

 

  

  

  

 

(e)           To the extent an expense or in-kind benefit provided pursuant to this Agreement constitutes a “deferral of compensation” within the meaning of Code Section 409A (1) the expenses will be reimbursed to Executive as promptly as practical and in any event not later than the last day of the calendar year after the calendar year in which the expenses are incurred, (2) the amount of expenses eligible for reimbursement or in-kind benefits provided during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided in any other calendar year, (3) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit.

 

  

  

  

IN WITNESS WHEREOF, this Amended and Restated Agreement has been executed by the Executive and the Company, as approved by the Board of Directors by Unanimous Written Consent, by its duly authorized representative, as of the date first above written.

 

	
Executive:

 

 

           

/s/ Sankaram Mantripragada              

Sankaram Mantripragada

	
AntriaBio, Inc.

 

 

By:  /s/ Nevan Elam                                                                                     

Name:  Nevan Elam

Title:  CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]